Compare ULH & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ULH | ENTA |
|---|---|---|
| Founded | 1932 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 390.3M | 382.7M |
| IPO Year | 2004 | 2012 |
| Metric | ULH | ENTA |
|---|---|---|
| Price | $13.89 | $14.41 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $20.00 | ★ $20.40 |
| AVG Volume (30 Days) | 50.2K | ★ 236.1K |
| Earning Date | 05-12-2026 | 05-11-2026 |
| Dividend Yield | ★ 1.74% | N/A |
| EPS Growth | N/A | ★ 29.93 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,461,708,000.00 | $102,814,000.00 |
| Revenue This Year | $2.73 | $7.76 |
| Revenue Next Year | $5.12 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 16.48 |
| 52 Week Low | $11.73 | $6.44 |
| 52 Week High | $30.76 | $17.15 |
| Indicator | ULH | ENTA |
|---|---|---|
| Relative Strength Index (RSI) | 37.64 | 59.39 |
| Support Level | $13.05 | $13.19 |
| Resistance Level | $18.76 | $15.48 |
| Average True Range (ATR) | 1.02 | 0.76 |
| MACD | -0.13 | 0.22 |
| Stochastic Oscillator | 8.35 | 74.04 |
Universal Logistics Holdings Inc is an asset-light provider of customized transportation and logistics solutions throughout the United States, and in Mexico, Canada, and Colombia. It offers services such as truckload, brokerage, intermodal, dedicated, and value-added services. The firm has three reportable segments, namely contract logistics, intermodal, and trucking. The company generates the key revenue from Contract Logistics, which provides value-added and dedicated transportation services to support inbound and internal logistics requirements of industrial manufacturers and retailers, generally under contractual arrangements of one year or longer. Geographically, the firm generates the majority of its revenue from the United States, followed by Mexico, Canada, and Colombia.
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.